TrialCancer immunology, immunotherapy : CII2023

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.

Tomoki Naoe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.